ArticleEJHaem2025

Assessment of the Tolerability and Optimal Dosing of the Combination of Brentuximab Vedotin and Lenalidomide in Patients With Relapsed or Refractory T-cell Lymphoma: Results of a Single-centre Phase 1 Dose-escalation Study.

Carrie van der Weyden et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.